Managing Psoriasis in Patients with Dyslipidemia (Persistently Elevated Cholesterol and/or Triglycerides)
Patients with psoriasis who also have dyslipidemia — defined by the persistent elevation of serum cholesterol and/or triglycerides — require a management approach that addresses both conditions together. The cardiovascular profile of psoriasis patients makes this combination clinically significant.
Clinical scenario
Dyslipidemia refers to the persistent elevation of serum cholesterol and/or triglycerides. In the context of psoriasis, this comorbidity carries added weight: psoriasis itself is recognised as an atherosclerotic cardiovascular disease (ASCVD) risk-enhancing condition, which has direct implications for how lipid abnormalities are evaluated and managed in these patients.
Treatment approach — partial overview
Lipid management with statin therapy, guided by national cholesterol guidelines, is central to this protocol. Because psoriasis is classified as an ASCVD risk-enhancing condition, it may favour earlier initiation of appropriate lipid-lowering therapy compared with the general population.
Full stratification criteria and regimen details in the structured protocol →
References
- Dyslipidemia refers to the persistent elevation of serum cholesterol and/or triglycerides.
- Antihypertensives and statins may be used as in the general population.
- In the 2018 updated guidelines, psoriasis was deemed an ASCVD risk-enhancing condition favoring early initiation of statin therapy.
DOI: 10.1016/j.jaad.2018.11.058
View source ↗